The high potent API market is experiencing steady expansion as drug development strategies increasingly emphasize targeted and high-efficacy therapies. The market is projected to grow from US$ 28.82 billion in 2024 to US$ 50.01 billion by 2031, recording a CAGR of 8.3% during the forecast period.









